Overall, these results indicate that exogenous expression of human NEXN by AAV-mediated gene delivery could prevent cardiomyopathy and restore cardiac function in G645del mice, demonstrating the high feasibility and efficacy of AAV-mediated in vivo gene therapy for DCM that caused by NEXN mutations in patients. Here, NEXN is linked to cardiomyopathy.